Your neurologist will advise the best treatment option for your child with SMA. 

Zolgensma is available on the Pharmaceutical Benefits Scheme (PBS) for children under 9 months of age, symptomatic and diagnosed with SMA Type 1, or children who do not yet have symptoms but do have one, two or three copies of the SMN2 gene.  

If your child has developed an immunity to AAV9, which is naturally found in the environment, they will not benefit from Zolgensma treatment. As such, all children being considered for treatment with Zolgensma will be tested for the AAV9 antibody, and if they show a response, they will be ineligible for this treatment. As AAV9 antibodies decline over time, children under 9 months age can be retested to check eligibility.